Eight months after Briumvi’s initial green light in the U.S., TG Therapeutics is preparing to debut its multiple sclerosis antibody on the world stage. | European specialty pharmaceutical company Neuraxpharm will throw TG an upfront payment of $140 million—plus an additional $12.5 million upon Briumvi’s first EU launch—to chip in on commercialization of TG’s CD20-targeting drug outside the United States. Under the deal, TG is eligible to receive another $492.5 million in milestones.
